about
Structure of the AAA ATPase p97Crystal structure of the M-fragment of alpha-catenin: implications for modulation of cell adhesionNovel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based designStructure-guided design of alpha-amino acid-derived Pin1 inhibitorsDiscovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolutionCrystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognitionThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).Crystallization of the Fab fragment of the tumour-specific antibody PR1A3.S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.Structure of (±)-egenineConformation of cyclodipeptides. factor analysis: a convenient tool for simplifying conformational studies of condensed poly-ring systems: prolyltype cyclopeptidesSynthesis, X-ray structure and high-resolution NMR spectroscopy of methyl 3-azido-2,3-dideoxy-alpha-D-arabino-hexopyranosideConformational analysis of the first observed non-proline cis-peptide bond occurring within the complementarity determining region (CDR) of an antibodyMolecular basis of AKAP specificity for PKA regulatory subunitsCrystallization of an antitumour antibody SM3 complexed with a peptide epitopeStructure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular ActivityEstablishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1
P50
Q27629334-64E3671A-AA33-4B6B-B1A7-7241283ACC8AQ27633124-B4E74C3B-B628-4A09-90B7-1CC695A4F233Q27654001-629A42FC-D49B-45C4-8719-3AA00250B25EQ27658516-008FBFDA-0DCA-4A77-B837-8C4FD7BA74B8Q27664950-23266812-5880-46DF-ADF9-4AEF21464A0EQ27766057-1C6A14E3-B41A-4C29-91EB-CED1B0D4710EQ38736457-4B873CA4-46FE-49D8-95B7-DAC51B48D9F9Q39762997-1EC5D4F6-2A59-4A5A-9721-6C6CE7F25DC6Q47663755-A7C0C5AE-B12D-410E-ADC5-962B3A14C353Q47982755-EC8F28AE-D529-498D-99D9-D6DFE5CDE2A6Q54998724-BA9F52E5-8AC6-4485-8DCD-2080CD80EF24Q58834534-25200B31-FEA4-46F7-ACEF-3A9DB9A56425Q58834539-5CF60223-4923-4142-8908-A000262BDB58Q73714392-6F330DF5-EF9B-4E0F-B926-EA5A41EEB066Q77593289-C1392CBC-385D-45D8-8E92-733448FEF901Q79326012-973A7329-A818-4052-8A3F-E569F982BEF8Q80427112-372D71EC-0983-4AE0-AD7C-99454A4C019AQ92143977-42BD3123-1E04-4C16-8C26-8189AB88AB69Q92945609-C2C69011-6B02-45A3-8FD9-1ACE7AB3E219
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pawel Dokurno
@ast
Pawel Dokurno
@en
Pawel Dokurno
@es
Pawel Dokurno
@nl
type
label
Pawel Dokurno
@ast
Pawel Dokurno
@en
Pawel Dokurno
@es
Pawel Dokurno
@nl
prefLabel
Pawel Dokurno
@ast
Pawel Dokurno
@en
Pawel Dokurno
@es
Pawel Dokurno
@nl
P106
P1153
6603356640
P31
P496
0000-0002-7332-8889